Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial

ABSTRACT: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genodermatosis with severe blistering. No curative treatment is available. Scientific data indicated that epigallocatechin-3-gallate (EGCG), a green tea extract, might improve the phenotype of RDEB patients. In a multicentre, rand...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Orphanet J Rare Dis
Päätekijät: Chiaverini, Christine, Roger, Coralie, Fontas, Eric, Bourrat, Emmanuelle, Bourdon-Lanoy, Eva, Labrèze, Christine, Mazereeuw, Juliette, Vabres, Pierre, Bodemer, Christine, Lacour, Jean-Philippe
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2016
Aiheet:
Letter to the Editor
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4807580/
https://ncbi.nlm.nih.gov/pubmed/27015660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-016-0411-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia